Chapter 12. Use of Lipid-Lowering Agents in the Prevention of Cardiovascular Disease

  1. Salim Yusuf DPhil, FRCPC, FRSC Research Chair Professor of Medicine Director Vice President Research3,4,5,
  2. John A Cairns MD, FRCPC Professor of Medicine Former Dean6,
  3. A John Camm MD British Heart Foundation Professor Head of Cardiac7,
  4. Ernest L Fallen MD, FRCPC Professor Emeritus8 and
  5. Bernard J Gersh MB, ChB, DPhil Consultant Professor of Medicine9
  1. R Alan Failor MD Clinical Professor of Medicine1 and
  2. Jeffrey L Probstfield MD Director Professor of Medicine (Cardiology)2

Published Online: 21 MAY 2010

DOI: 10.1002/9781444309768.ch12

Evidence-Based Cardiology, Third Edition

Evidence-Based Cardiology, Third Edition

How to Cite

Failor, R. A. and Probstfield, J. L. (2009) Use of Lipid-Lowering Agents in the Prevention of Cardiovascular Disease, in Evidence-Based Cardiology, Third Edition (eds S. Yusuf, J. A. Cairns, A. J. Camm, E. L. Fallen and B. J. Gersh), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444309768.ch12

Editor Information

  1. 3

    McMaster University, Canada

  2. 4

    Population Health Research Institute, McMaster University, Hamilton Health Sciences, Canada

  3. 5

    Hamilton Health Sciences, Hamilton, Ontario, Canada

  4. 6

    Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada

  5. 7

    St George's University of London, London, UK

  6. 8

    McMaster University Faculty of Health Sciences, Hamilton, Ontario, Canada

  7. 9

    Mayo Clinic College of Medicine, Rochester, MN, USA

Author Information

  1. 1

    Division of Metabolism, Endocrinology and Nutrition, University of Washington, Seattle, WA, USA

  2. 2

    Clinical Trials Service Unit, University of Washington School of Medicine, Seattle, WA, USA

Publication History

  1. Published Online: 21 MAY 2010
  2. Published Print: 13 NOV 2009

ISBN Information

Print ISBN: 9781405159258

Online ISBN: 9781444309768



  • lipid-lowering agents - preventing of cardiovascular disease;
  • 3-hydroxy-3-methylglutaryl-coenzyme A (HMG - CoA) - effective LDL-C lowering agents;
  • decrease in low-density lipoprotein cholesterol;
  • HMG-CoA reductase inhibitors - agents having powerful LDL-C lowering effect;
  • atorvastatin and rosuvastatin - powerful members of statin class;
  • nicotinic acid - clinical effect on triglycerides and HDL


This chapter contains sections titled:

  • Introduction

  • Use of individual lipid-altering agents

  • HMG-CoA reductase inhibitors (statins)

  • Nicotinic acid

  • Bile acid-sequestering agents (resins) (see Table 12.2)

  • Fibric acid derivatives (see Table 12.2)

  • Selective cholesterol absorption inhibitor

  • Novel agents

  • Combination therapy

  • Informed decisions about “gray zones”

  • Costs and cost effectiveness of lipid alterations for CHD prevention

  • Future directions

  • Conclusion

  • References